In contrast, mixed well-to-poorly differentiated adenocarcinomas were less frequent in the BRAF/NRAS group (three of six cases, 50.0%) than in the KRAS (33 of 39 cases, 84.6%) or WT (21 of 27 cases, 77.7%) groups (Table 6). This evidence concerns the gene NRAS and adenocarcinoma.